XTX Topco Ltd Increases Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Key Points

• XTX Topco Ltd increased its stake in Collegium Pharmaceutical by 159.2% in Q1, now holding 21,317 shares valued at approximately $636,000.
• Collegium Pharmaceutical announced a stock buyback plan allowing for the repurchase of $150 million in shares, indicating the company's belief that its stock is undervalued.
• In its latest earnings report, Collegium missed EPS expectations by $0.01, despite a revenue growth of 22.7% year-over-year, reporting $177.76 million for the quarter.

XTX Topco Ltd boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 159.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,317 shares of the specialty pharmaceutical company's stock after acquiring an additional 13,092 shares during the quarter. XTX Topco Ltd owned 0.07% of Collegium Pharmaceutical worth $636,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. MetLife Investment Management LLC boosted its position in Collegium Pharmaceutical by 8.5% in the 4th quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock worth $573,000 after purchasing an additional 1,558 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Collegium Pharmaceutical in the 1st quarter worth approximately $244,000. Janney Montgomery Scott LLC acquired a new stake in Collegium Pharmaceutical in the 1st quarter valued at approximately $439,000. GAMMA Investing LLC lifted its stake in Collegium Pharmaceutical by 8,947.4% during the first quarter. GAMMA Investing LLC now owns 17,552 shares of the specialty pharmaceutical company's stock worth $524,000 after purchasing an additional 17,358 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Collegium Pharmaceutical by 38.8% during the fourth quarter. Millennium Management LLC now owns 185,918 shares of the specialty pharmaceutical company's stock worth $5,327,000 after buying an additional 51,972 shares during the period.

Wall Street Analysts Forecast Growth

COLL has been the subject of a number of research analyst reports. Wall Street Zen cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, July 5th. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $43.75.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL traded up $1.99 during midday trading on Friday, reaching $34.93. The stock had a trading volume of 809,540 shares, compared to its average volume of 363,819. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The stock has a market cap of $1.12 billion, a P/E ratio of 28.63 and a beta of 0.68. The firm has a fifty day simple moving average of $30.65 and a two-hundred day simple moving average of $29.65. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The firm had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. During the same quarter last year, the firm earned $1.45 earnings per share. The company's revenue was up 22.7% compared to the same quarter last year. On average, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical announced that its board has initiated a share buyback plan on Monday, July 7th that authorizes the company to buyback $150.00 million in shares. This buyback authorization authorizes the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its shares are undervalued.

Insider Activity

In related news, Director John Gordon Freund sold 6,601 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $30.62, for a total transaction of $202,122.62. Following the transaction, the director owned 70,658 shares of the company's stock, valued at $2,163,547.96. This represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.